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ABSTRACT Since their discovery, protein tyrosine phos-
phatases have been speculated to play a role in tumor sup-
pression because of their ability to antagonize the growth-
promoting protein tyrosine kinases. Recently, a tumor sup-
pressor from human chromosome 10q23, called PTEN or
MMAC1, has been identified that shares homology with the
protein tyrosine phosphatase family. Germ-line mutations in
PTEN give rise to several related neoplastic disorders, in-
cluding Cowden disease. A key step in understanding the
function of PTEN as a tumor suppressor is to identify its
physiological substrates. Here we report that a missense
mutation in PTEN, PTEN-G129E, which is observed in two
Cowden disease kindreds, specifically ablates the ability of
PTEN to recognize inositol phospholipids as a substrate,
suggesting that loss of the lipid phosphatase activity is re-
sponsible for the etiology of the disease. Furthermore, expres-
sion of wild-type or substrate-trapping forms of PTEN in
HEK293 cells altered the levels of the phospholipid products
of phosphatidylinositol 3-kinase and ectopic expression of the
phosphatase in PTEN-deficient tumor cell lines resulted in the
inhibition of protein kinase (PK) ByAkt and regulation of cell
survival.
Glioblastoma is one of the most common and malignant forms
of cancer. It is often characterized by the constitutive activa-
tion of epidermal growth factor (EGF)-dependent signaling
pathways caused by the amplification of members of the EGF
receptor family of protein tyrosine kinases (PTKs). The prod-
ucts of tumor-suppressor genes may attenuate these signaling
pathways, and therefore, their loss through deletion or muta-
tion may contribute to tumor progression. The frequent loss of
heterozygosity at tumor-suppressor loci is often used to iden-
tify tumor-suppressor genes. The 10q23 region of human
chromosome 10 is frequently deleted or mutated in a wide
variety of tumor types, most frequently in glioblastoma, en-
dometrial cancer, and prostate cancer, indicating the presence
of a tumor-suppressor gene at this locus. PTEN was subse-
quently identified as this tumor suppressor and was found to
contain the catalytic signature motif detected in all members
of the protein tyrosine phosphatase (PTP) family (1, 2).
Importantly, PTEN appears to be lost frequently in advanced
cancers, suggesting that its deletion may not be the transform-
ing event but that PTEN may inhibit other cellular functions
necessary for tumor progression (3, 4).
Importantly, germ-line transmission of mutations in PTEN
was shown to give rise to a related set of disorders, including
Cowden disease, that are characterized by numerous small
benign tumors and an increased incidence of other malignant
growths (5–7). The detection of germ-line mutations in these
neoplastic disorders verifies that PTEN is the tumor suppres-
sor residing on human chromosome 10q23. This conclusion is
supported by the recent findings that PTEN knockout mice
develop tumors similar to those found in Cowden disease (8).
A key step in establishing the cellular function of PTEN is
the identification of its physiological substrates. Recently, two
groups have identified different candidate substrates for
PTEN. Tamura et al. (9) report that overexpression of PTEN
results in changes in cell adhesion and spreading and suggest
that these effects result from the the dephosphorylation of
the PTK focal adhesion kinase (FAK). In contrast, Maehama
and Dixon (10) have shown that PTEN recognizes phospha-
tidylinositol phosphate (PtdInsP) as a substrate. Our initial
studies demonstrating catalytic activity in PTEN indicated that
it preferred highly acidic or multiply phosphorylated substrates
(11). This may explain why, in certain contexts, PTEN will
dephosphorylate polyphosphorylated molecules such as FAK
or PtdInsP (11, 12). Nevertheless, the important question
remains as to which multiply phosphorylated molecules, pro-
tein or otherwise, are the physiologically relevant targets of
PTEN.
Significantly, we have demonstrated previously that the
majority of missense mutations isolated from tumor and
Cowden disease samples ablate the protein phosphatase ac-
tivity of PTEN (11). One exception is a missense mutation that
changes a glycine residue in the catalytic signature motif to a
glutamate (PTEN-G129E; see ref. 11). Although there was no
adverse effect on the protein phosphatase activity of PTEN,
this G129E mutation was isolated from two independent
Cowden-disease kindreds, indicating that it abolishes the
tumor-suppressor activity of PTEN (5, 12). Therefore, this
mutation can be used as an important indicator to determine
whether a proposed function of PTEN is specific for its role as
a tumor suppressor.
We analyzed the PTEN-G129E Cowden disease mutation
and found that this mutation specifically inhibits the recogni-
tion of PtdInsPs by PTEN. Additionally, we show that expres-
sion of PTEN in mammalian cells results in changes in
PtdIns(3,4,5)P3 levels, and expression of PTEN in two inde-
pendent glioblastoma cell lines results in the disruption of
signaling downstream of phospahatidylinositol 3-kinase (PI
3-kinase) to PKByAkt and BAD. Significantly, we also show
that expression of PTEN in LnCaP cells, a prostate-tumor cell
line, abrogates cell survival and that this effect is inhibited by
the expression of a constitutively activated form of PKB.
Therefore, we believe that the physiological function of PTEN
is to antagonize signaling downstream of PI 3-kinase by
dephosphorylating PtdInsPs.
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PTEN Phosphatase Assays. Recombinant wild-type and
mutant forms of PTEN were expressed in Eschirichia coli and
purified by glutathione-affinity chromatography (11). The
purified proteins were assayed with polyGluTyr as described
(11). Release of 32Pi from radiolabeled PtdInsPs was deter-
mined by performing a modified Bligh and Dyer extraction
(13). The upper phase (containing inorganic phosphate) was
removed, dried, and resuspended in a 1 M trichloroacetic
acidy1% ammonium molybdate solution. After extraction with
2 vol of tolueneyisobutylalchohol (1:1 volyvol), the upper
phase was removed and counted. Site selectivity was deter-
mined by incubating recombinant PTEN or SHIP (a gift from
C. Erneux, Free University, Brussels) with radiolabeled
PtdIns(3,4,5)P3, and the lipid products of these reactions were
analyzed by TLC or HPLC (13). The phospholipids were
extracted by performing the modified Bligh and Dyer extrac-
tion described, and the resulting lower phases were dried,
resuspended in 20 ml of chloroformymethanol (2:1 volyvol),
and applied to an oxalate-activated silica 60 TLC plate. Plates
were developed in methanolychloroformywateryammonia
(100:75:25:15).
Determination of PtdIns[3,4,5]P3 Levels. HEK293 cells were
transfected via calcium phosphate coprecipitation with 20 mg
of DNA per 10-cm dish. The calcium phosphatezDNA copre-
cipitate was removed by washing with PBS 16 hr after addition,
and the cells were returned to growth medium for 36 hr before
harvesting. Cotransfection of PTEN and p110 constructs were
performed by using 9.5 mg of each plasmid DNA. Transfection
efficiency was determined by including a green fluorescent
protein expression plasmid (1 mg) in all transfections and was
shown to be 80%. Phospholipids were extracted from the cells
exactly as described (14). PtdIns(3,4,5)P3 levels were assayed
by using a ligand displacement assay (14) and were normalized
to total protein.
Expression of PTEN in Glioblastoma Cell Lines. PTEN
retroviral expression vectors were constructed in pBabePuro
(15). After transfection into packaging lines, the viral super-
natants were harvested, diluted with growth medium, and
incubated with U87MG or U373MG cells for 8 hr at 32°C in
the presence of polybrene. Infected cells were selected with
puromycin (2 mgyml), and drug-resistant colonies were ex-
panded to generate clonal cell lines. Cell lysis and immunoblots
were performed essentially as described (16). Protein levels
were determined by the method of Bradford using BSA as a
standard, and equal protein was loaded in each lane. Anti-
bodies to PTEN were generated in rabbits by using a C-
terminal peptide of PTEN (ENEPFDEDQHTQITKV) con-
jugated to keyhole limpet hemocyanin. Antibodies to PKBy
AKT, phospho-PKByAkt (specific to phosphorylated Ser-473)
and phospho-BAD were purchased from New England Bio-
labs.
Expression of PTEN in LnCaP Cells. Cells were transfected
by using cationic lipids (Transfast, Promega) at a DNAylipid
ratio of 1. Cells were incubated with the DNA–lipid complexes
for 12 hr, and transfected cells then were identified based on
the expression of a cotransfected GFP vector or by performing
immunoflourescence by using antibodies to the HA-epitope
tag located at the N terminus of PTEN, essentially as described
(17).
RESULTS
Activity of PTEN Toward Inositol Phospholipids. Recom-
binant PTEN, produced in E. coli (11), was assayed for its
ability to release 32Pi from radiolabeled PtdIns(3,4,5)P3 or
polyGluTyr (Fig. 1A). As expected, wild-type PTEN catalyzed
the dephosphorylation of both substrates (Fig. 1 A). Remark-
ably, the activity of PTEN-G129E toward PtdIns(3,4,5)P3 was
reduced by '90% relative to the wild-type enzyme while still
retaining activity toward polyGluTyr (Fig. 1A). A catalytically
inactive mutant of PTEN (PTENC124S) was unable to de-
phosphorylate polyGluTyr or PtdIns(3,4,5)P3, indicating that
the phosphatase activity was not caused by a bacterial con-
taminant. In addition, cdc14, a dual-specificity phosphatase
closely related to PTEN, was also unable to dephosphorylate
PtdIns(3,4,5)P3, demonstrating that recognition of this phos-
pholipid substrate is not a general property of other, even
closely related, dual-specificity phosphatases. These data,
demonstrating that the PTEN-G129E mutation specifically
ablates the activity of PTEN toward phosphorylated inositol
lipids, demonstrates that the lipid phosphatase, rather than the
protein phosphatase, activity of PTEN is required for it to
FIG. 1. PTEN is a PtdIns 3-phosphatase. (A) Recombinant PTEN was incubated with radiolabeled polyGluTyr and PtdIns(3,4,5)P3, and the
release of 32Pi was measured as described. (B) PtdIns(3,4,5)P3, labeled at the 3 position, was incubated with PTEN or SHIP for 0 or 60 min, and
the reaction products were resolved on TLC plates and visualized by autoradiography.
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function as a tumor suppressor and that loss of the lipid
phosphatase activity results in Cowden disease.
Site Specificity of PTEN Within PtdIns(3,4,5)P3. To deter-
mine whether PTEN recognizes specific sites in the inositol
ring of PtdIns(3,4,5)P3, lipid substrate, labeled exclusively in
the 3 position with 32P, was incubated with PTEN or SHIP, a
well characterized 5-phosphatase (18). The products of these
reactions were analyzed by TLC. Incubation with SHIP yielded
a radiolabeled product with the expected mobility of
PtdIns(3,4)P2 (Fig. 1B). However, no labeled lipid products
were generated following treatment with PTEN under condi-
tions where .50% of the 32P was lost from the substrate (Fig.
1B). The site selectivity of PTEN was confirmed by HPLC
analysis of similar reactions by using 3H- and 3-32P-labeled
Ins(1,3,4,5)P4 in which the only products detected were 32Pi
and [3H]Ins(1,4,5)P3 (data not shown). In addition to
PtdIns(3,4,5)P3, PTEN also hydrolyzed the other potential
products of PI 3-kinase, PtdIns(3)P and PtdIns(3,4)P2, with the
following rank order based on relative percent hydrolysis:
PtdIns(3,4,5)P3 5 PtdIns(3,4)P2 . PtdIns3P . Ins(1,3,4,5)P4.
The specificity of PTEN for 3-phosphorylated inositol lipids
indicates that it may function as a negative regulator of PI
3-kinase-mediated signaling and distinguishes PTEN from
other known lipid phosphatases.
PTEN Inhibits PI 3-Kinase-Dependent Signaling. The po-
tential for PTEN to antagonize PI 3-kinase signaling was
further investigated in mammalian cells (Fig. 2). Transient
expression of PTEN in HEK293 cells lowered the levels of
PtdIns(3,4,5)P3 (Fig. 2) from 1 pmolymg to 0.7 pmolymg.
Importantly, PTEN-C124S, in which the catalytic cysteine has
been mutated to serine, resulted in an increase in the levels of
PtdIns(3,4,5)P3 (Fig. 2) from 1 pmolymg to 2 pmolymg. The
accumulation of PtdIns(3,4,5)P3 in response to expression of
PTEN-C124S is likely because of the ability of this form of
PTEN to behave as a ‘‘substrate-trapping’’ mutant, resulting in
a stable complex with the lipid substrate that protects it from
dephosphorylation by endogenous phosphatases (19). The
accumulation of PtdIns(3,4,5)P3 in the presence of a substrate-
trapping mutant confirms that PtdIns(3,4,5)P3 is a physiolog-
ical target of PTEN (19, 20). Expression of a constitutively
activated PI 3-kinase (p110-CAAX) resulted in elevated levels
of PtdIns(3,4,5)P3 that were reduced '60% following coex-
pression with PTEN and were increased '4.5-fold when
coexpressed with PTEN-C124S (Fig. 2). The ability of PTEN
to decrease PtdIns(3,4,5)P3 levels produced by p110-CAAX
further indicates that this phosphatase exerts its effects on the
products of PI 3-kinase rather than by dephosphorylating the
tyrosine residues responsible for recruiting the p85-p110 PI
3-kinase complex to the membrane.
Importantly, we detected defects in PI 3-kinase signaling in
tumor cell lines that have lost their endogenous PTEN genes
through deletion or mutation. Signaling downstream of PI
3-kinase was assessed in two of these PTEN-deficient cell lines,
U87 MG and U373 MG, by determining the phosphorylation
status of PKByAkt, a kinase whose activation depends on
PtdIns(3,4,5)P3 or PtdIns(3,4)P2, two products of PI 3-kinase
(21). Clonal cell lines were generated in U87 MG and U373
MG in which PTEN expression was restored by infection with
recombinant retroviruses (Fig. 3). The parental cell lines
exhibited high basal levels of phosphorylated PKByAkt,
whereas in every wild-type PTEN-expressing clonal cell line
the basal levels of activated PKByAkt were significantly low-
ered (Fig. 3). Expression of a catalytically inactive mutant of
PTEN, PTEN-R130M, had no effect on basal PKByAkt
activation (Fig. 3). Similarly, no effect on PKByAkt activation
was observed in a U373 MG (PTEN-SRVE no. B9) clone
infected with an unstable mutant of PTEN (Fig. 3). After
reconstitution of PTEN expression in the tumor lines, activa-
tion of PKByAkt by insulin or platelet-derived growth factor
was unaffected (Fig. 3), suggesting that there are regulatory
mechanisms that allow for the generation of PtdIns(3,4,5)P3
following growth factor stimulation. The activation of PKBy
Akt was completely inhibited by wortmannin in the tumor-cell
lines (Fig. 3), indicating that the increase in PKByAkt phos-
phorylation was PI 3-kinase-dependent.
Regulation of Cell Survival. One of the downstream sub-
strates of PKByAkt is the death-effector protein BAD (22),
phosphorylation of which has been linked to the promotion of
cell survival (23). Although expression of PTEN in both U87
MG and U373 MG resulted in the reduction of BAD phos-
phorylation (Fig. 3B), we did not detect evidence of apoptosis
in the PTEN-expressing clones. However, expression of wild-
type PTEN in LnCaP cells, a PTEN-deficient prostate-cancer
cell line, resulted in a decrease in the number of PTEN-positive
cells recovered relative to controls expressing the catalytically
inactive mutant PTEN-C124S (Fig. 4). In this assay, the
Cowden disease mutation PTEN-G129E behaved similarly to
PTEN-C124S, consistent with the ablation of the tumor-
suppressor activity of PTEN by this mutation (Fig. 4). Signif-
icantly, coexpression of a constitutively active, membrane-
targeted PKByAkt (24) completely reverted the PTEN phe-
notype in that PTEN-positive cells could now be recovered
despite the presence of wild-type PTEN (Fig. 4).
DISCUSSION
PTEN is a newly defined tumor-suppressor gene that has been
implicated in a wide variety of cancers and in a series of related
disorders that are characterized by a predispostion to cancer
(1, 2, 25–28). Although these studies offer many insights into
the biology of PTEN, they do not address the molecular
mechanism of PTEN function, which requires the identifica-
tion of its physiological substrates. However, this has become
an area of controversy. Tamura et al. (9) have suggested that
PTEN disrupts cell spreading and migration by dephosphory-
lating FAK. In contrast, Maehema and Dixon (10) have shown
FIG. 2. Expression of PTEN-antagonized PI 3-kinase. HEK293
cells were transfected with PTEN or PTENC124S in combination with
the p110 subunit of PI 3-kinase or an activated, membrane-bound PI-3
kinase (p110-CAAX). The resulting levels of PtdIns(3,4,5)P3 were
determined as described and were normalized to total protein. Data
are expressed as pmol of PtdIns(3,4,5)P3 per mg of protein. These data,
from a single experiment, are representative of three experiments that
yielded similar results.
Biochemistry: Myers et al. Proc. Natl. Acad. Sci. USA 95 (1998) 13515
that, in certain contexts, PTEN can dephosphorylate the lipid
second messenger PtdInsP. However, both of these studies fall
short of demonstrating that the ability of PTEN to dephos-
phorylate FAK or PtdInsP is related to its tumor-suppressive
function. In light of the facts that previous studies have shown
that PTEN prefers highly acidic or multiply phosphorylated
substrates (11) and that FAK and PtdInsP share these prop-
erties, one must view these results with caution, as they may
result from nonspecific interactions between PTEN and highly
charged molecules (12).
Significantly, we have been able to show that a single point
mutation in PTEN, PTEN-G129E, specifically ablates the
ability of PTEN to recognize phospholipids as substrates. In
contrast, Tamura et al. (9) found that the PTEN-G129E point
mutation behaves essentially like wild-type PTEN in their
assays of cell spreading. Even though this mutation does not
alter the ability of PTEN to recognize proteinaceous sub-
strates, the fact that it has been identified in two independent
Cowden disease kindreds indicates that this mutation would be
expected to impair the tumor-suppressor activity of PTEN (5,
11). Therefore, these findings demonstrate that the lipid
phosphatase activity rather than the protein phosphatase
activity of PTEN is important for its tumor-suppressive activity
and that FAK, at least in this respect, is not a relevant target
of the phosphatase.
Characterization of the lipid phosphatase activity of PTEN
demonstrates that it shows specificity for phosphatidylinositols
phosphorylated at the 3 position. This represents the first
phosphatidylinositol phosphatase with specificity for the lipid
products of PI 3-kinase and suggests that PTEN may function
to antagonize the growth-promoting signals generated by PI
3-kinase. Indeed, overexpression of PTEN in mammalian cells
disrupted the PI 3-kinase-dependent production of
PtdIns(3,4,5)P3. Furthermore, expression of a catalytically
inactive mutant of PTEN, PTEN-C124S, which may function
as a substrate trap, results in the accumulation of
PtdIns(3,4,5)P3, indicating that PTEN may function in vivo to
antagonize PI 3-kinase-dependent signaling.
Importantly, signaling downstream of PI 3-kinase is altered
in two different glioblastoma cell lines, U87 MG and U373
MG, which have lost expression of PTEN because of mutation
or deletion of both alleles. Both cell lines exhibited elevated
levels of active, phosphorylated PKByAkt, a serineythreonine
kinase whose activation requires the production of
PtdIns(3,4,5)P3 or PtdIns(3,4)P2 (21, 29). Restoration of
PTEN expression by retroviral transduction resulted in the
reduction of activated PKByAkt as is evident from the ob-
served reduction in the phosphorylation of PKByAkt and in
reduced levels of phosphorylated BAD, an apoptosis regulator
FIG. 3. Expression of PTEN in glioblastoma cell lines decreases the amount of activated PKByAKT. PTEN expression was reconstituted in
U87MG (A) or U373MB glioblastoma (B) cell lines by infection with recombinant retrovirus. Confluent dishes were either left untreated, stimulated
with insulin (10 mgyml for 10 min) or platelet-derived growth factor (50 ngyml for 10 min), or pretreated with wortmannin (150 nM for 30 min),
stimulated with both insulin (10 mgyml) and platelet-derived growth factor (50 ngyml) for 10 min, and then lysed. Equal amounts of protein were
loaded for each cell line, and immunoblots were probed with antibodies to PTEN, PKByAkt (PKB), phospho-PKByAkt (P-PKB), or phosphorylated
BAD (P-BAD) and visualized by using enhanced chemiluminescence reagents.
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that is a known in vivo substrate of PKByAkt (22). Signifi-
cantly, insulin or platelet-derived growth factor stimulation of
these cell lines resulted in the stimulation of PKByAkt regard-
less of whether PTEN expression had been reconstituted,
suggesting that there are mechanisms in place which, in
response to growth factor stimulation, serve to regulate the
activity of PTEN and allow the production of PtdIns(3,4,5)P3.
This is especially important given that PTEN is widely ex-
pressed, including cell lines that produce PtdIns(3,4,5)P3 in
response to insulin.
Although the reconstitution of PTEN decreased the levels
of phosphorylated BAD, we were unable to detect evidence
of apoptosis in these cell lines. PKByAKT is thought to affect
cell survival in many cell types by phosphorylating BAD or
inactivating GSK3b (23, 30). Reconstitution of PTEN in
LnCaP cells, a PTEN-deficient prostate-cancer cell line,
resulted in the inhibition of cell survival. Importantly, ex-
pression of the PTEN-G129E Cowden disease point muta-
tion does not result in the abrogation of cell survival. This
observation indicates that the lipid phosphatase activity of
PTEN is required for these effects on cell survival. The
properties of the PTEN-G129E mutant emphasize the re-
quirement of the lipid phosphatase activity for the tumor-
suppressor function of PTEN. Furthermore, the PTEN-
dependent induction of apoptosis was completely inhibited
by coexpressing a constitutively active, membrane-targeted
form of PKByAkt indicating that PTEN, by dephosphory-
lating phosphatidylinositides, is an upstream regulator of
PKByAkt and, at least in LNCAP cells, serves to regulate
survival signals. Thus, in some cell types, PTEN functions as
a tumor suppressor to inhibit the PKByAKT-dependent
survival signals that are activated in response to 3-phosphor-
ylated phosphatidylinositols.
The failure of PTEN to regulate cell survival in the glio-
blastoma cell lines suggests that the generation of phosphati-
dylinositol 3-phosphates plays other roles during tumor pro-
gression. In fact, PI 3-kinase has been implicated in the
regulation of a wide variety of cellular processes (31). There-
fore, by dephosphorylating the products of PI 3-kinase, PTEN
is likely to be involved in the regulation of many of these
processes. Significantly, both PI 3-kinase and PKByAkt have
been isolated as transforming oncogenes in retroviruses (32,
33). These observations indicate that PI 3-kinase and PKBy
Akt function in a signaling pathway promoting growth and
survival. Our data demonstrate that PTEN functions to sup-
press these growth-promoting and survival signals by dephos-
phorylating the phospholipid products of PI 3-kinase. Our data
provide a molecular basis for the development of Cowden
disease, as loss of the lipid phosphatase activity of PTEN leads
to the accumulation of the products of PI 3-kinase and results
in the neoplastic pathologies characteristic of the disease.
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